AAT Presentation
14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Christopher U. Missling, PhD View Presentation
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders
Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders NEW YORK, NY – June 6, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
NEW YORK, NY – May 20, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug…
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
Detailed Data to be Presented at Upcoming Scientific Meeting NEW YORK, NY – May, 18 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…
Anavex Reports Fiscal Second Quarter 2016 Financial Results
New York, NY – May 11, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three…
Speaker Session: BIO 2016 International Convention
Event: Casting a Wider Net in Alzheimer’s Research: The Diversity of Today’s Approaches and Signs of Progress Date/Time: Tuesday, June 7, 2016 at 3:30 p.m. PT Location: Room West 3006, West Hall, Moscone Center, San Francisco, CA
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
NEW YORK, NY – April 8, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration…
Anavex Annual Stockholders Meeting
Event: 2016 Annual Meeting of Stockholders of Anavex Life Sciences Corp. Date/Time: Friday, May 6, 2016 10:00 a.m. ET Location: Offices of K & L Gates LLP, 599 Lexington Avenue, New York, NY 10022
33rd Camerino-Cyprus Symposium
Event: Presentation by Christopher U. Missling, PhD, President and Chief Executive Officer Date/Time: Tuesday, May 17, 2016 15:40 to 16:10 Location: Palazzo Ducale Piazza Cavour, Camerino, Italy
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Results Demonstrate Significant Reversal in Cognitive Deficit, Inflammation and Alzheimer’s-like Amyloid Pathology NEW YORK, NY – March 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…